{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:30:38Z","timestamp":1775187038053,"version":"3.50.1"},"reference-count":47,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Little is known about cardiovascular safety profiles for monoclonal antibody products that received the FDA Emergency Use Authorization for COVID-19. In this study, data from the FDA Adverse Event Reporting System from the first quarter of 2020 to the second quarter of 2022 were used to investigate cardiovascular safety signals associated with seven monoclonal antibody products (casirivimab + imdevimab, bamlanivimab, bamlanivimab + etesevimab, sotrovimab, tocilizumab, bebtelovimab, tixagevimab + cilgavimab) in COVID-19 patients. Disproportionality analyses were conducted using reporting odds ratio and information component to identify safety signals. About 10% of adverse events in COVID-19 patients were cardiovascular adverse events. Four monoclonal antibody products (casirivimab + imdevimab, bamlanivimab, bamlanivimab + etesevimab, and bebtelovimab) were associated with higher reporting of hypertension. Tocilizumab was associated with higher reporting of cardiac failure and embolic and thrombotic event. Casirivimab + imdevimab and bamlanivimab were also associated with higher reporting of ischemic heart disease. No cardiovascular safety signals were identified for sotrovimab and tixagevimab + cilgavimab. The results indicate differential cardiovascular safety profiles in monoclonal antibodies. Careful monitoring of cardiovascular events may be considered for certain COVID-19 patients at risk when they are treated with monoclonal antibodies.<\/jats:p>","DOI":"10.3390\/ph15121472","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T01:58:46Z","timestamp":1669600726000},"page":"1472","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19"],"prefix":"10.3390","volume":"15","author":[{"given":"Jingrui","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Scientific Affairs, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyuan","family":"Jing","sequence":"additional","affiliation":[{"name":"Independent Researcher, Marlboro, NJ 07746, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Arias, M., Oliveros, H., Lechtig, S., and Bustos, R.H. (2022). Biologics in COVID-19 So Far: Systematic Review. Pharmaceuticals, 15.","DOI":"10.3390\/ph15070783"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e0092622","DOI":"10.1128\/spectrum.00926-22","article-title":"Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis","volume":"10","author":"Tao","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/jmv.27623","article-title":"The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials","volume":"94","author":"Lin","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_5","first-page":"Cd014945","article-title":"SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19","volume":"6","author":"Hirsch","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.amjmed.2022.06.019","article-title":"Beneficial and Harmful Effects of Monoclonal Antibodies for the Treatment and Prophylaxis of COVID-19: Systematic Review and Meta-Analysis","volume":"135","author":"Hernandez","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_7","first-page":"1","article-title":"Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: A systematic review and network meta-analysis","volume":"50","author":"Deng","year":"2022","journal-title":"Infection"},{"key":"ref_8","first-page":"159","article-title":"A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: Implications for the treatment of COVID-19","volume":"21","author":"Diaby","year":"2021","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40801-022-00300-y","article-title":"Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine\/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Zhao","year":"2022","journal-title":"Drugs\u2014Real World Outcomes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11096-022-01457-w","article-title":"An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19","volume":"44","author":"Luo","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1080\/14740338.2021.1962846","article-title":"Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data","volume":"20","author":"Singh","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Castagn\u00e9, B., Viprey, M., Martin, J., Schott, A.M., Cucherat, M., and Soubrier, M. (2019). Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220178"},{"key":"ref_13","first-page":"7","article-title":"COVID-19: Treatments and the potential for cardiotoxicity","volume":"28","author":"Birkhoelzer","year":"2021","journal-title":"Br. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40801-021-00229-8","article-title":"Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS)","volume":"8","author":"Yuan","year":"2021","journal-title":"Drugs\u2014Real World Outcomes"},{"key":"ref_15","unstructured":"US Food & Drug Administration (2022, November 22). FDA Adverse Event Reporting System, Available online: https:\/\/open.fda.gov\/data\/faers\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.spinee.2013.09.056","article-title":"Postmarketing safety of biologics and biological devices","volume":"14","author":"Woo","year":"2014","journal-title":"Spine J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/jmv.26429","article-title":"Late onset infectious complications and safety of tocilizumab in the management of COVID-19","volume":"93","author":"Pettit","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.21037\/jgo-21-863","article-title":"A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer","volume":"13","author":"Masuishi","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jjco\/hyv182","article-title":"Bevacizumab safety in Japanese patients with colorectal cancer","volume":"46","author":"Hatake","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111685","DOI":"10.1016\/j.biopha.2021.111685","article-title":"COVID-19 and metabolic comorbidities: An update on emerging evidences for optimal therapies","volume":"140","author":"Hua","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 397, 1637\u20131645.","DOI":"10.1101\/2021.02.11.21249258"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): An open-label, multicentre, randomised, controlled, phase 3 trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial","volume":"327","author":"Sarkar","year":"2022","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV Antibody Combination and Outcomes in Outpatients with COVID-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1038\/s41467-022-32551-2","article-title":"Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19","volume":"13","author":"Chew","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cpt.2405","article-title":"First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients with COVID-19","volume":"110","author":"Chen","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"ref_33","unstructured":"Centers for Medicare & Medicaid Services (2022, November 22). COVID-19 Monoclonal Antibodies, Available online: https:\/\/www.cms.gov\/monoclonal."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"ref_35","unstructured":"US Food & Drug Administration (2022, November 22). Emergency Use Authorization, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization#coviddrugs."},{"key":"ref_36","unstructured":"US Food & Drug Administration (2022, November 22). Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cirmi, S., El Abd, A., Letinier, L., Navarra, M., and Salvo, F. (2020). Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers, 12.","DOI":"10.3390\/cancers12040826"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"692828","DOI":"10.3389\/fphar.2022.692828","article-title":"Acute Kidney Injury Associated with Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","article-title":"Quantitative methods in pharmacovigilance: Focus on signal detection","volume":"26","author":"Hauben","year":"2003","journal-title":"Drug Saf."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chiappini, S., Vickers-Smith, R., Guirguis, A., Corkery, J.M., Martinotti, G., Harris, D.R., and Schifano, F. (2022). Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). Pharmaceuticals, 15.","DOI":"10.3390\/ph15060675"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Raschi, E., Fusaroli, M., Gatti, M., Caraceni, P., Poluzzi, E., and De Ponti, F. (2022). Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal. Pharmaceuticals, 15.","DOI":"10.3390\/ph15050645"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/bcp.14546","article-title":"Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports","volume":"87","author":"Goldman","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7150\/ijms.10656","article-title":"Association between statin use and cancer: Data mining of a spontaneous reporting database and a claims database","volume":"12","author":"Fujimoto","year":"2015","journal-title":"Int. J. Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Noren","year":"2011","journal-title":"Stat. Methods Med. Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/12\/1472\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:28Z","timestamp":1760146048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/12\/1472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,26]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["ph15121472"],"URL":"https:\/\/doi.org\/10.3390\/ph15121472","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,26]]}}}